Jake Simson - Jun 9, 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role: Director
Signature: /s/ Lara Meisner, Attorney-in-Fact
Stock symbol: BCAX
Transactions as of: Jun 9, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/10/2025, 04:27 PM
Previous filing: Jun 2, 2025
Next filing: Jun 13, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Simson Jake	Director	BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON	/s/ Lara Meisner, Attorney-in-Fact	2025-06-10	0001863094

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCAX	Stock Option (Right to Buy)	Award	$0	+23.7K		$0.00	23.7K	Jun 9, 2025	Common Stock	23.7K	$11.48	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.